SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Evidence for tetrodotoxin-resistant spontaneous myogenic contractions of mouse isolated stomach that are dependent on acetylcholine.

Cai, W; Makwana, R; Straface, M; Gharibans, A; Andrews, PLR; Sanger, GJ (2022) Evidence for tetrodotoxin-resistant spontaneous myogenic contractions of mouse isolated stomach that are dependent on acetylcholine. Br J Pharmacol, 179 (6). pp. 1187-1200. ISSN 1476-5381 https://doi.org/10.1111/bph.15685
SGUL Authors: Andrews, Paul Lyn Rodney

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB) | Preview
[img] Microsoft PowerPoint (Figures S1-S3) Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (4MB)
[img] Microsoft Word (.docx) (Data S1) Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (38kB)

Abstract

BACKGROUND AND PURPOSE: Gastric pacemaker cells, interstitial cells of Cajal (ICC), are believed to initiate myogenic (non-neuronal) contractions. These become damaged in gastroparesis, associated with dysrhythmic electrical activity and nausea. We utilised mouse isolated stomach to model myogenic contractions and investigate their origin and actions of interstitial cells of Cajal modulators. EXPERIMENTAL APPROACH: Intraluminal pressure was recorded following distension with a physiological volume; tone, contraction amplitude and frequency were quantified. Compounds were bath applied. KEY RESULTS: The stomach exhibited regular large amplitude contractions (median amplitude 9.0 [4.7-14.8] cmH2 O, frequency 2.9 [2.5-3.4] c.p.m; n = 20), appearing to progress aborally. Tetrodotoxin (TTX, 10- 6 M) had no effect on tone, frequency or amplitude but blocked responses to nerve stimulation. ω-conotoxin GVIA (10- 7 M) ± TTX was without effect on baseline motility. In the presence of TTX, (1) atropine (10- 10 -10- 6 M) reduced contraction amplitude and frequency in a concentration-related manner (pIC50 7.5 ± 0.3 M for amplitude), (2) CaCC channel (previously ANO1) inhibitors MONNA and CaCCinh-A01 reduced contraction amplitude (significant at 10- 5 , 10- 4 M respectively) and frequency (significant at 10- 5 M), and (3), neostigmine (10- 5 M) evoked a large, variable, increase in contraction amplitude, reduced by atropine (10- 8 -10- 6 M) but unaffected (exploratory study) by the H1 receptor antagonist mepyramine (10- 6 M). CONCLUSIONS AND IMPLICATIONS: The distended mouse stomach exhibited myogenic contractions, resistant to blockade of neural activity by TTX. In the presence of TTX, these contractions were prevented or reduced by compounds blocking interstitial cells of Cajal activity or by atropine and enhanced by neostigmine (antagonised by atropine), suggesting involvement of non-neuronal ACh in their regulation.

Item Type: Article
Additional Information: © 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Keywords: ACh, ANO1, CaCC, interstitial cells of Cajal, myogenic contractions, nausea, stomach, ACh, ANO1, CaCC, interstitial cells of Cajal, myogenic contractions, nausea, stomach, 1115 Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy
Journal or Publication Title: Br J Pharmacol
ISSN: 1476-5381
Language: eng
Dates:
DateEvent
14 February 2022Published
27 October 2021Published Online
6 September 2021Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDTakeda Pharmaceuticals North AmericaUNSPECIFIED
UNSPECIFIEDBowel Research UKUNSPECIFIED
PubMed ID: 34519057
Web of Science ID: WOS:000711480400001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113856
Publisher's version: https://doi.org/10.1111/bph.15685

Actions (login required)

Edit Item Edit Item